Goldman Sachs Upgrades MorphoSys to Neutral, Raises Price Target to $9.25

Benzinga · 09/15/2023 08:11
Goldman Sachs analyst Rajan Sharma upgrades MorphoSys (NASDAQ:MOR) from Sell to Neutral and raises the price target from $3.5 to $9.25.